These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3907937)

  • 1. Transfusional iron overload.
    Marcus RE; Huehns ER
    Clin Lab Haematol; 1985; 7(3):195-212. PubMed ID: 3907937
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

  • 3. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S
    J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron overload: pathogenesis and treatment with chelating agents.
    Huebers H
    Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 7. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 12. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
    Brittenham GM; Allen CJ; Farrell DE; Harris JW
    Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG; Dashkova NG
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 18. Iron chelation therapy in sickle cell anemia.
    Cohen A; Schwartz E
    Am J Hematol; 1979; 7(1):69-76. PubMed ID: 507048
    [No Abstract]   [Full Text] [Related]  

  • 19. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.